Unternehmensübersicht
Geron Corporation operates as a commercial-stage biopharmaceutical enterprise dedicated to the development of therapeutic products specifically targeted at oncology. The company functions within the healthcare sector, more precisely categorized under the biotechnology industry, which implies a focus on biological agents and innovative drug discovery processes. Currently, Geron reports a market capitalization of $896.76M and generates annual revenue of $183.88M while maintaining an employee count of 258. These valuation figures indicate that the market assigns a significant size premium to the entity relative to its revenue base, suggesting that the stock price is driven largely by expectations of future pipeline value rather than current earnings generation. The disparity between the market cap and the revenue figure highlights that the company's valuation is primarily anchored in its developmental assets and potential for future commercialization of its oncology treatments.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $183.88M, yet this revenue generated a net income of -$83,500,000 and an EBITDA of -$51,079,000, revealing a substantial gap between top-line sales and bottom-line profitability. This negative net income despite positive revenue indicates a cost structure where operating expenses, likely driven by research and development expenditures, significantly exceed gross profits. The free cash flow stands at -$78,356,248, which signifies that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or dilution. Margin analysis shows a gross margin of 97.4%, reflecting high pricing power or low cost of goods sold typical in biotechnology, contrasted sharply by an operating margin of -17.7% and a profit margin of -45.4%. These negative operating and profit margins demonstrate that while the product manufacturing is efficient, the broader operational overhead and R&D investments are heavily eroding overall profitability. In terms of leverage, the company holds $357.92M in cash against $121.99M in debt, resulting in a debt-to-equity ratio of 54.01, which suggests a balance sheet that is highly leveraged in terms of equity but maintains a robust absolute cash position. The current ratio of 4.66 indicates a strong ability to cover short-term liabilities with short-term assets, pointing to excellent short-term liquidity despite the long-term cash burn. Return on equity is recorded at -33.0% and return on assets at -5.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, a common characteristic for early-to-mid stage biotechnology firms still in the investment phase.
Bewertungsanalyse
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, whereas the forward P/E is 17.50, implying that the market anticipates a trajectory toward profitability in the future periods reflected in the forward estimate. The price-to-book ratio stands at 3.97, indicating that the market values the company at nearly four times its book value, suggesting a premium assigned to the intangible assets and intellectual property within the pipeline. Alternative valuation metrics provide further context, with a price-to-sales ratio of 4.88 and an EV/EBITDA of -12.94, which suggests that investors are pricing the stock based on sales multiples rather than earnings, typical for pre-profitable biotech entities. The 52-week trading range spans from a low of $1.04 to a high of $2.01, meaning the current price sits at a level that reflects recent volatility but remains within the historical bounds of the past year. The beta value is 0.62, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to larger-cap equities.
Growth & Income
Revenue growth year-over-year is recorded at 1.0%, while earnings growth is N/A due to the company's continued losses, implying that revenue expansion is currently flat rather than accelerating and that earnings are not growing faster than revenue. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are reinvested into the growth of the business rather than distributed to shareholders. The absence of a dividend payout aligns with the financial strategy of retaining capital to fund ongoing research and development activities necessary to advance the oncology product pipeline. Overall, the growth and income profile is characterized by flat revenue growth, zero dividend yield, and a capital allocation strategy focused entirely on funding future therapeutic developments rather than providing immediate income returns.